Identification of novel prognostic targets in glioblastoma using bioinformatics analysis

Xiaofeng Yin, Quansheng Wu, Zheng Hao and Laizhao Chen*

Abstract

Background: Glioblastoma (GBM) is the most malignant grade of glioma. Highly aggressive characteristics of GBM and poor prognosis cause GBM-related deaths. The potential prognostic biomarkers remain to be demonstrated. This research builds up predictive gene targets of expression alterations in GBM utilizing bioinformatics analysis.

Methods and results: The microarray datasets (GSE15824 and GSE16011) associated with GBM were obtained from Gene Expression Omnibus (GEO) database to identify the differentially expressed genes (DEGs) between GBM and non-tumor tissues. In total, 719 DEGs were obtained and subjected to Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) for function enrichment analysis. Furthermore, we constructed protein–protein Interaction (PPI) network among DEGs utilizing Search Tool for the Retrieval of Interacting Genes (STRING) online tool and Cytoscape software. The DEGs of degree > 10 was selected as hub genes, including 73 upregulated genes and 21 downregulated genes. Moreover, MCODE application in Cytoscape software was employed to identify three key modules involved in GBM development and prognosis. Additionally, we used the Gene expression profiling and interactive analyses (GEPIA) online tool to further confirm four genes involving in poor prognosis of GBM patients, including interferon-gamma-inducible protein 30 (IFI30), major histocompatibility complex II-DM alpha (HLA-DMA), Prolyl 4-hydroxylase beta polypeptide (P4HB) and reticulocalbin-1 (RCN1). Furthermore, the correlation analysis indicated that the expression of IFI30, an acknowledged biomarker in glioma, was positively correlated with HLA-DMA, P4HB and RCN1. RCN1 expression was positively correlated with P4HB and HLA-DMA. Moreover, qRT-PCR and immunohistochemistry analysis further validated the upregulation of four prognostic markers in GBM tissues.

Conclusions: Analysis of multiple datasets combined with global network information and experimental verification presents a successful approach to uncover the risk hub genes and prognostic markers of GBM. Our study identified four risk- and prognostic-related gene signatures, including IFI30, HLA-DMA, P4HB and RCN1. This gene sets contribute a new perspective to improve the diagnostic, prognostic, and therapeutic outcomes of GBM.

Keywords: Glioblastoma multiform, Bioinformatics analysis, Prognosis, Biomarker
Introduction

Glioblastoma multiform (GBM), the most common brain cancer in central nervous system (CNS), is identified as grade IV glioma, with approximately 5.36 new cases per 100,000 population [1–3]. Due to its highly aggressive characteristics, a 5-year overall survival (OS) of GBM patients treated with maximum surgical excision plus chemoradiotherapy ranges from 0.01 to 29.1% [4, 5]. Surgical resection followed by adjuvant temozolomide-based chemotherapy and radiotherapy is the current feasible treatment of GBM patients [6]. A subset of GBM displays a high heterogeneity, which is strongly associated with morphology characteristics, molecular changes and immunotherapy [1]. Defining the molecular targets for diagnosis and reexamination is crucial for therapeutic action and prognostic outcome of GBM patients.

Several studies has described that significant molecular biomarkers in GBM were identified as prognostic or therapeutic factors, such as O6-methylguanine-DNA methyltransferase (MGMT), epidermal growth factor receptor (EGFR) and isocitrate dehydrogenase (IDH) [7, 8]. GBM patients with IDH wild-type anaplastic astrocytoma had poor overall survival that that in patients with IDH mutant type [9]. According to the classification of CNS tumors, IDH status should be included in the diagnosis of glioma. In addition, IDH mutation inhibitors are effective against IDH1/2 mutated gliomas [10]. Although phase I clinical trials demonstrated a promising antitumor activity, further evidence indicated the limitations of IDH1-mutant inhibitors against glioma growth. A study demonstrated that an inhibitor targeting IDH1-mutant conferred radiation resistance on IDH1-mutant tumor cells [11]. The identification of novel biomarkers may be helpful to improve the clinical outcome of GBM patients and provide a combined approach.

Bioinformatics analysis is a well-orchestrated tool for screening tumor-specific genes and prognosis-relevant biomarkers, which can contribute to the development of cancer treatment [12]. At present, microarray and RNA-seq data downloaded from Gene Expression Omnibus (GEO) database can be used to detect genes transcription expression levels and to provide the technical support for monitoring mRNA expression and cell function prediction [13]. For example, Alshabi et al. reported that high levels of RPL36A and AP1S1 were associated with poor prognosis and pathogenesis of GBM by analyzing lin7A-silenced data samples [14]. Zhou et al. have reported that the expression of RRM2 and CEP55 is responsible for prognosis of GBM [15].

Although numerous reports have identified differentially expressed genes in GBM tumorigenesis via bioinformatic analysis, the prognostic value of these genes has not become widely acceptable in clinical practice. Systematic study of identifying multiple prognostic genes will provide better understanding of GBM therapeutic targets, prognostic judgment and illness monitoring. The aim of present study was to characterize the differentially expressed genes in GBM datasets and identify more genes with prognostic value.

Here, we analyzed the GBM profiles that were downloaded from the GEO database and performed the identification of differentially expressed genes (DEGs) between the GBM tissues and the non-tumor brain tissues. Afterwards, Gene ontology (GO) terms and Kyoto Encyclopedia of Gene and Genome (KEGG) pathways associated with DEGs were explored to elucidate the gene enrichment in GBM. Moreover, protein–protein
interaction (PPI) networks and the hub genes were identified according to degree parameters and clustering coefficient. Furthermore, six hub genes were subject to prognostic analysis. Through an integrative bioinformatics strategy, we identified four novel biomarkers (IFI30, HLA-DMA, P4HB and RCN1) as the interests of GBM prognosis assessment. Moreover, the expression of candidates genes in GBM tissues were assessed via qRT-PCR and immunohistochemistry analysis. In short, these results indicated that the four genes might have potential value in prognosis and diagnosis of GBM.

Results

Expression analysis of DEGs in GBM

GBM gene expression profiles from the GEO database, GSE15824 and GSE16011, including 10 non-tumor brain samples and 167 GBM tissue samples, were subjected to identification of DEGs. We identified DEGs between GBM samples and non-tumor samples with the cut-off of log2 (Fold Change) (log2|FC|) > 2 and adjusted $p < 0.05$. In GSE15824 dataset, 1517 DEGs were screened out, including 723 downregulated and 794 upregulated genes in GBM samples. Of 3017 DEGs in GSE16011 dataset, 1471 were downregulated and 1546 were upregulated. The volcano plots presented the distributions of differentially expressed genes (Fig. 1A). The heat maps demonstrated the gene expression levels in two datasets (Fig. 1B). Subsequently, the intersection of DEGs in these two datasets was analyzed using Draw Venn Diagram online tools (http://bioinformatics.psb.ugent.be/webtools/Venn/). As shown in Fig. 1C, a total of 719 DEGs were identified in GBM tissues among the two datasets, as compared to the non-tumor tissues.

Functional enrichment analysis of DEGs in GBM

Function annotation analysis of the 719 DEGs was performed utilizing DAVID online tool [16]. The upregulated DEGs were significantly enriched in the biological processes (BP): innate immune response, inflammatory response, cell adhesion, apoptotic process and positive regulation of NF-kB signaling (Fig. 2A). The upregulated DEGs were significantly enriched in the cellular component (CC): extracellular exosome, plasma membrane, cytosol and extracellular matrix (Fig. 2B). The upregulated DEGs were significantly enriched in the molecular function (MF): protein binding, protein homodimerization activity, receptor binding and signal transducer activity (Fig. 2C). Moreover, KEGG pathway enrichment analysis indicated that the upregulated DEGs were involved in PI3K–AKT signaling pathway, cell adhesion molecules, Hippo signaling pathway, Toll-like receptor signaling pathway and NF-kB signaling pathway (Fig. 2D). In addition, the GO enrichment of downregulated DEGs is shown in Table 1.

PPI network and hub gene analysis of DEGs in GBM

All DEGs were subject to PPI network analysis utilizing STRING database [17] with the highest confidence (greater than 0.9). Next, the data file downloaded from STRING analysis was visualized utilizing Cytoscape software. Generally, the PPI network covered 324 nodes and 1284 edges. To identify the hub genes, the nodes with a connectivity degree greater than 10 in the whole PPI network were collected. A total of 94 genes were regarded as hub genes, including 73 upregulated genes and 21 downregulated genes.
Furthermore, MCODE application results were indicative of three significant modules (node score cut-off = 0.2, k-core = 2, depth from seed = 100). All network scoring of the three modules were more than 5.0. Module 1, module 3 and module 10 were significant modules in the PPI network. A total of 62 nodes and 504 edges were included in Module 1 (Fig. 3A), and a total of eight nodes and 18 edges were included in Module 3 (Fig. 3B). In addition, there were five nodes and 10 edges in Module 10 (Fig. 3C).

Identification of prognostic genes
To further identify the key prognostic genes, GEPIA online tool covering 163 GBM tissues and 207 non-tumor brain tissues data from the TCGA was utilized for the validation of hub gene expression. Moreover, the overall survival analysis was also performed. The results demonstrated that six hub genes not only were upregulated in GBM tissue samples (all \( p < 0.05 \)), but also were markedly related to worse prognosis of GBM patients, including IFI30, HLA-DMA, P4HB, RCN1, FN1 and PYCARD (all \( p < 0.05 \),
Fig. 2 Functional enrichment analysis of DEGs in GBM. A–C Gene ontology (GO) analysis of DEGs. D Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis of DEGs

Table 1 GO and pathway enrichment analysis of downregulated DEGs in GBM

| Category             | Term                                      | Count, n | p value   |
|----------------------|-------------------------------------------|----------|-----------|
| GOTERM_BP_DIRECT     | GO:0043547 ~ positive regulation of GTPase activity | 17       | 0.0099    |
|                      | GO:0035556 ~ intracellular signal transduction | 15       | 0.0027    |
|                      | GO:0007155 ~ cell adhesion                 | 14       | 0.0192    |
|                      | GO:0006468 ~ protein phosphorylation       | 13       | 0.0387    |
| GOTERM_CC_DIRECT     | GO:0016021 ~ integral component of membrane | 99       | 0.0019    |
|                      | GO:0005886 ~ plasma membrane               | 90       | 4.13E−05  |
|                      | GO:0005622 ~ intracellular                 | 31       | 0.013     |
|                      | GO:0005887 ~ integral component of plasma membrane | 30       | 0.043     |
| GOTERM_MF_DIRECT     | GO:0005524 ~ ATP binding                   | 32       | 0.0383    |
|                      | GO:0005509 ~ calcium ion binding           | 18       | 0.0409    |
|                      | GO:0004674 ~ protein serine/threonine kinase activity | 12       | 0.0261    |
|                      | GO:0004672 ~ protein kinase activity       | 11       | 0.0437    |
| KEGG_PATHWAY         | hsa04144:Endocytosis                      | 9        | 0.0211    |
|                      | hsa04010:MAPK signaling pathway            | 9        | 0.0273    |
|                      | hsa04723:Retrograde endocannabinoid signaling | 8       | 0.00055   |
|                      | hsa04921:Oxytocin signaling pathway        | 7        | 0.0198    |
Fig. 4). In addition, among the six hub genes, the high levels of four genes were related to worse DFS of GBM patients (all $p < 0.05$, Fig. 5). These results indicated that IFI30, HLA-DMA, P4HB and RCN1 might be considered as oncogene and prognostic genes in GBM.

**Correlation analysis between prognostic genes**

Spearman’s correlation analysis was carried out to analyze the expression correlation between the four prognostic genes (IFI30, HLA-DMA, P4HB and RCN1) (Fig. 6A). As displayed in Fig. 6B–E, the level of IFI30 was positively correlated with HLA-DMA ($R = 0.79$, $p < 0.001$), P4HB ($R = 0.3$, $p < 0.001$) and RCN1 ($R = 0.22$, $p < 0.01$). Additionally, the expression of RCN1 was positively correlated with P4HB ($R = 0.43$, $p < 0.001$) and HLA-DMA ($R = 0.19$, $p < 0.01$).

**Principal component analysis (PCA) verifies the grouping ability of selected prognostic genes**

To reduce high-dimensionality genes with poor prognostic significance into a limited number of principal components, PCA was performed to detect the prognostic-related genes between the GBM and LGG or non-tumor brain tissues. PCA identifies new variables, the principal components, which are linear combinations of the original prognostic genes. The components have a sample-like pattern with a weight for each gene. The principal components are normalized eigenvectors of the covariance matrix of the genes and ordered according to how much of the variation present in the data they contain. Each component can then be interpreted as the direction, uncorrelated to previous components, which maximizes the variance of the samples when projected onto the component. Then we looked at the proportion of the variance present in all genes contained...
within each principal component. The result is that the dimensionality can be reduced from the number of genes down to two dimensions, while still retaining information that separates GBM from brain-cortex or LGG from GBM. The scatter plots indicated that principal components 1 (PC1) contributed to more than 80% of the variation in either group GBM vs brain-cortex or GBM vs Hippocampus. And the first two principal components were used to generate stable clusters. Figure 7 reveals that GBM group was well separated from either brain-cortex or hippocampus in the first principal component. However, PCA did not separate samples based on GBM and LGG clearly.

Expression analysis of prognostic genes by qRT-PCR and immunohistochemistry
Clinical study has confirmed that IFI30 expression was upregulated in GBM tissues and was a significantly poor prognostic marker of patients with glioma [18, 19]. However, the expression HLA-DMA, P4HB and RCN1 in GBM was not elucidated. In this research, we
further confirmed the levels of the above prognostic genes in GBM tissue samples and normal brain specimens by qRT-PCR analysis and IHC assay. Of the mRNA levels analyzed, HLA-DMA, P4HB and RCN1 demonstrated differential expression between GBM tissues and normal brain samples (all $p < 0.001$, Fig. 8A–C). Moreover, we performed IHC analysis to complement our qRT-PCR result as well as to detect protein expression in GBM tissues. The IHC analysis displayed that GBM tissues were expressing significant high levels of HLA-DMA, P4HB and RCN1 (Fig. 8D). Due to the specificities of antibodies, IHC analysis is required for identification and evaluation of cancer biomarkers, to explore protein function and verify the accuracy of prognostic tests.

**Fig. 5** Identification of prognostic genes. Disease-free survival (DFS) of selected genes (RCN1, P4HB, HLA-DMA and IFI30) in GBM using TCGA database and Gepia online tool.
Discussion

Despite the effective conventional GBM therapeutics clinically, several patients with GBM suffer from cancer recrudesce and metastasis, as an aggressive malignant brain tumor in CNS [20]. Therefore, it is crucial to explore regulators driving GBM tumor...
Fig. 7 Principal component analysis between the GBM and LGG or non-tumor brain tissue groups based on screened prognostic-related genes. PCA 2D scatter plots and scree plots showed within-sample variation between GBM and brain-cortex (A), brain-hippocampus (B) or LGG (C) based on screened prognostic-related gene set. Each color of dot represents individual tumor.

Fig. 8 The expression of P4HB, HLA-MDA and RCN1 in GBM and normal brain tissues. A-C qRT-PCR analysis of P4HB, HLA-MDA and RCN1 mRNA expression in GBM tissues (n = 15) and normal brain tissues (n = 10). Data were showed as mean ± SD and analyzed with unpaired t test. **p < 0.01, ***p < 0.001.

D Immunohistochemical analysis of P4HB, HLA-MDA and RCN1 expression in GBM. E IHC score in GBM tissues and normal brain tissues. Data were showed as mean ± SD and analyzed with two-way ANOVA, followed by Bonferroni’s multiple comparisons test. ***p < 0.001.
development and to develop biomarkers that can better predict postoperative patients with aggressive GBM.

Bioinformatics methods have emerged since the advent of high-throughput sequencing and microassay technology. Moreover, several studies have utilized TCGA or GEO datasets to identify numerous biomarkers related to worse prognosis and survival in GBM [21, 22]. In the present research, we thoroughly identified and analyzed a total of 719 DEGs from two microarray datasets. Ninety-four hub genes were found in the PPI network while six genes were interestingly found in the independent expression test of the TCGA database. Additionally, it was confirmed in clinical tissues that the four genes (RCN1, P4HB, HLA-DMA and IFI30) were overexpressed in GBM tissues compared with normal brain tissues.

IFI30 is considered to be a typical regulating immune regulator belonging to the γ-interferon stimulated gene family [19], responsible for the activation of tumor progression. Its role in the development of glioma mainly depends on its coding protein γ-interferon-inducible lysosomal thiol reductase (GILT) [23]. Liu et al. detected the expression of IFI30 in glioma with wild-type isocitrate dehydrogenase (IDH) and the infiltration response in immune cells by TCGA datasets analysis [18]. They found that the level of IFI30 was higher in GBM specimens than in low-grade glioma (LGG) specimens. Moreover, its expression was also increased in wild-type IDH samples [18]. Interestingly, the analysis indicated that the upregulation of IFI30 contributed to worse prognosis and immunosuppression which triggered extracellular matrix dysfunction and angiogenesis in GBM [18]. However, the exact molecular interactions that associated with IFI30 in GBM procession remain less clear.

The results in this study verified that the expression of IFI30 was positively associated with the mRNA expression pattern of HLA-DMA, P4HB and RCN1. Previous studies suggested that the three genes (HLA-DMA, P4HB, RCN1) whose expression was related to IFI30 level in GBM exerted tumorigenic functions in malignant phenotypes. HLA-DMA is mainly associated with breast cancer [24]. It indicated that tumors that express HLA-DMA might contribute to the enhanced levels of immunity response and patient outcome [24]. P4HB is an autophagy-related gene which plays a role in diagnosis of kidney renal clear cell carcinoma [25]. In addition, liver cancer cells with overexpressed P4HB favored cancer cell growth and epithelial–mesenchymal transition, and also enhanced cancer cell chemoresistance [26]. RCN1 is upregulated in oral squamous cell carcinoma, prostatic cancer and non-small cell lung cancer [27–29]. RCN1 served as a biomarkers for tumor diagnosis and prognosis.

The most significant correction is IFI30 vs HLA-DMA. As a peptide processor, HLA-DMA catalyzes peptide conversion on classical MHCII proteins [30] and protects empty MHC class II molecules from functional inactivation during efficient presentation of protein antigens [31]. HLA-DMA has been known to be involved in cancer progression and drug-resistance [32]. There is an evidence that the enrichment of HLA-DMA in gastric cancer RNAseq expression profiling involves the activation of antigen processing and presentation pathway [33]. Another research reported that increased level of HLA-DMA is related to immune response in GBM, as a novel target for GBM diagnosis and treatment [34]. We gave a new confirmation for that HLA-DMA is expected to become a biomarker for GBM prognosis.
P4HB is an endoplasmic reticulum chaperone protein with overexpression in numerous tumor tissues [35]. P4HB has a significant prognostic potential in bladder urothelial carcinoma by serving as an autophagy-related gene [36]. Consistent with the prominent role of P4HB during tumorigenesis, upregulation of P4HB expression is frequently observed during cell resistance to drug. It has been shown that inhibition of P4HB expression in glioma cells results in suppression of temozolomide resistance by regulating endoplasmic reticulum stress response [37]. In combination with the view that immune response in cellular stress is involved in dysfunction of endoplasmic reticulum [38], this study gave a predicting result that IFI30, a potential immune-associated target in GBM, was positively correlated with P4HB level.

RCN1, a monomeric cell surface-associated protein encoding an endoplasmic reticulum (ER)-resident Ca\(^{2+}\)-binding domain, plays a crucial role in cancer metastasis and development [39]. Although RCN1 is expressed in endothelial cells, the increase of RCN1 expression is indicative of tumor characteristics [40]. A recent study found that in nasopharyngeal carcinoma with sensitivity Adriamycin, the down-expression of RCN1 significantly enhanced cell drug-sensitivity [41]. In addition, RCN1 is molecular marker for the diagnosis and prognosis of non-small cell lung cancer [29]. Our data indicated that RCN1 has impact on OS and DFS rate of GBM patients for the first time and its potential oncogenic function would be related to IFI30 expression. It would be meaningful to confirm exact function of RCN1 in GBM in future.

Subsequently, we collected several clinical GBM tumor tissues and detected the expression levels of HLA-DMA, P4HB and RCN1 in GBM via qRT-PCR and IHC assays. The results indicated that HLA-DMA, P4HB and RCN1 expression was upregulated in GBM. However, clinical and therapeutic evidences that the genes function as prognostic are lacking. More follow-up studies will be performed to verify the prognostic role of these genes in patients with GBM. In fact, studies have reported that IFI30 and HLA-DMA could be related to immune response process [24, 42] which play tumor-regulatory roles in GBM [43]. The association between IFI30 or HLA-DMA and GBM immune microenvironment will be the topic of further research. In addition, recent reports have revealed that P4HB and RCN1 acted as tumor-suppressor factors in liver cancer [26], colon cancer [44], lung cancer [29] and prostate cancer [28]. In the future study, we may combine gene expression levels of P4HB or RCN1 and cell biological behavior analysis to further explore the pathogenesis of GBM.

**Conclusions**

This study identified four significant DEGs (IFI30, HLA-DMA, P4HB and RCN1) between GBM and normal brain tissues via analyzing two microarray datasets. The identification of novel biomarkers may be helpful to improve the clinical outcome of GBM patients and provide a combined approach. These four genes are potentially regarded as novel biomarkers for prognosis in GBM. It will contribute to the identification of GBM patients and probably result in a convenience of monitoring outcome of patients with GBM. However, this study had some limitations due to the limited sample size obtained from microassay datasets and the lack of survival analysis on adequate clinical samples. Future prospective research is indispensable to include a larger sample size and evaluate the clinical values of the four GBM biomarkers.
Methods
Microarray data and DEGs identification
GSE15824 and GSE16011 profiles were downloaded from the GEO database (https://www.ncbi.nlm.nih.gov/geo/). The GSE15824 dataset was generated utilizing the GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array platform and contained two non-tumor samples and twelve GBM samples (12 primary and 0 secondary). The GSE16011 dataset was generated using the GPL8542 Affymetrix GeneChip Human Genome U133 Plus 2.0 Array platform and contained eight non-tumor samples and 159 GBM samples (106 primary and 53 secondary). Limma package (version: 3.40.2) of R software and GEO2R online analysis was utilized to identify DEGs. The false positive results in GEO datasets were corrected by the adjusted p-value. Adjusted $p < 0.05$ and log$_2$ (fold Change) ($\log_2|FC|$) $> 2$ were identified as the thresholds for the screening of DEGs.

GO and KEGG pathway enrichment analysis
To comprehensively investigate the biological meaning behind DEGs intersection, the Database for Annotation, Visualization and Integrated Discovery (DAVID) (https://david.ncifcrf.gov/) [45, 46] was used to obtain the set of functional annotation. GO (http://www.geneontology.org/) is an extensively used tool for annotating genes with potential functions, such as molecular function (MF), biological pathways (BP) and cellular components (CC). KEGG enrichment analysis (https://www.kegg.jp/) is a practical resource for analytical study of gene functions and associated high-level genome functional information. $p < 0.05$ was regarded as the threshold value.

PPI network and modules analysis
The Search Tool for the Retrieval of Interacting Genes (STRING, http://string-db.org) is a public resource designed to analyze PPI information. In the present research, the STRING online tool was utilized to generate the full STRING network containing all DEGs. The required score (highest confidence) was set as greater than 0.9 to validate significant interactions. In addition, the STRING network file was downloaded and subject to visualization using Cytoscape software (version 3.5.1) [47]. The nodes with a degree greater than 10 were regarded as hub genes and applied for further analysis. Furthermore, the clusters in 94 hub genes were constructed using Molecular Complex Detection (MCODE) application (version 2.2) with Node score cut-off $= 0.2$, k-core $= 2$ and max depth $= 100$.

Expression levels and survival analysis of Hub genes in GBM
The gene expression levels and GBM patient survival were analyzed using the Gene expression profiling and interactive analyses (GEPIA, http://geopia.cancer-pku.cn/) [48]. The GEPIA contained 162 GBM samples and 207 non-tumor samples and the expression of hub genes was analyzed. In addition, the prognosis information of GBM
patients, including OS and disease-free survival (DFS), was also collected to identify the prognostic biomarkers among hub genes.

**GBM tissues collection and immunohistochemistry (IHC)**

This study was approved by the ethics committee of Second hospital of Shanxi Medical University. A total of 15 tumor samples were collected from patients with GBM after obtaining written informed consent between June 2016 and May 2020. All patients were diagnosed with GBM by two experienced pathologists and all patients did not undergo any treatment before surgery. A total of 10 normal brain tissues were isolated from patients with epilepsy. The sections of 4-μm thickness were collected from GBM and normal brain tissues, immobilized with 4% paraformaldehyde for 15 min, and then incubated with 0.3% H₂O₂ solutions for 20 min. After that, the sections were incubated with 5% BSA at room temperature to inhibit nonspecific binding. Anti-HLA-DMA (sc-134356, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-P4HB (ab137110, Abcam, Cambridge, UK) and anti-RCN1 (ab210404, Abcam) antibodies were used to stain with the specific proteins. The slides were washed four times, incubated with biotinylated secondary antibody for 1 h, and incubated with streptavidin-HRP reagent for 10 min. Next, the sections were placed in DAB kit (ab64238, Abcam) for incubation of 10 min. The images of tissues were captured with a microscope.

**RT-qPCR**

Total RNAs were isolated from GBM tissues using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). First-Strand Synthesis System Kit (Invitrogen) was used for cDNA synthesis. Next, qPCR was performed using Applied Biosystems™ PowerUp™ SYBR™ Green Mix (Applied Biosystems, Carlsbad, CA, USA) and specific primers. Primer sequences for target genes and reference genes are listed as following. HLA-DMA, forward primer: 5'-ATG GGA AAA TCC CGG TGT CC-3', reverse primer: 5'-GTT GTG ATA GGC AGG CCA CT-3'; P4HB, forward primer: 5'-TGC TGC GGA AAA GCA ACT TC-3', reverse primer: 5'-GTC ATC TCC TCC AGG GT-3'; RCN1, forward primer: 5'-ACG AGA GCA AGG AGA GGC TA-3', reverse primer: 5'-TCC TTC CAG ACT TGT GCC AC-3'; GAPDH, forward primer: 5'-GCT CTC TGC TCC TCC TGT TC-3', reverse primer: 5'-TTC CCG TTC TCA GCC TTG AC-3'. qPCR assays were performed on the iQ5 Real-time PCR system (Bio-Rad, Hercules, CA, USA).

**Correlation analysis**

GEPIA online tool was utilized for analyzing the correlation between the hub genes with Spearman's correlation analysis. \( p < 0.05 \) was considered as significant difference.

**Abbreviations**

GBM: Glioblastoma; DEGs: Differentially expressed genes; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; PPI: Protein–protein interaction; STRING: Search Tool for the Retrieval of Interacting Genes; GEPIA: Gene expression profiling and interactive analyses; IFN: Interferon-gamma-inducible protein; HLA-DMA: Major histocompatibility complex class II-DM alpha; P4HB: Prolyl 4-hydroxylase beta polypeptide; RCN1: Reticulocalbin-1; CNS: Central nervous system; OS: Overall survival; EGFR: Epidermal growth factor receptor; IDH: Isocitrate dehydrogenase; MGMT: O6-Methylguanine-DNA methyltransferase; GEO: Gene Expression Omnibus; DAVID: The Database for Annotation, Visualization and Integrated Discovery; MF: Molecular function; BP: Biological pathways; CC: Cellular components; MCODE: Molecular Complex Detection; DFS: Disease-free survival; IHC: Immunohistochemistry; IDH: Isocitrate dehydrogenase; LGG: Low-grade glioma.
Acknowledgements

None.

Author contributions

XF, QW and ZH wrote the main manuscript text. XF and LC prepared Figs. 1–8. All authors read and approved the final manuscript.

Funding

This research has been provided by the Applied Basic Research Project of Shanxi Province (20210302123266).

Availability of data and materials

The open-access datasets are available through the following URL: GSE15824 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15824) and GSE16011 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16011). All data generated or analyzed during this study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study involving human material were performed in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Second hospital of Shanxi Medical University. Informed consent was obtained from all patients included in this study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 20 August 2021   Accepted: 7 April 2022

Published online: 18 April 2022

References

1. Wirsching HG, Galanis E, Weller M. Glioblastoma. Handb Clin Neurol. 2016;134:381–97.
2. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842–50.
3. Hu M, et al. Human cytomegalovirus infection activates glioma activating transcription factor 5 via microRNA in a stress-induced manner. ACS Chem Neurosci. 2021;12(20):3947–56.
4. Marenco-Hillembrand L, et al. Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis. J Neurooncol. 2020;147(2):297–307.
5. Hu M, et al. ELF1 Transcription Factor Enhances the Progression of Glioma via ATFS promoter. ACS Chem Neurosci. 2021;12(7):1252–61.
6. Le Rhun E, et al. Molecular targeted therapy of glioblastoma. Cancer Treat Rev. 2019;80(101896):11.
7. Donson AM, et al. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer. 2007;48(4):403–7.
8. Padfield E, Ellis HP, Kurian KM. Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma. Front Oncol. 2015;5:5.
9. Turcan S, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483(7390):479–83.
10. Mondesir J, et al. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. J Blood Med. 2016;7:171–80.
11. Molenaar RJ, et al. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. Cancer Res. 2015;75(22):4790–802.
12. Huang X, et al. High Throughput Single Cell RNA sequencing, bioinformatics analysis and applications. Adv Exp Med Biol. 2018;840:5023.
13. Clough E, Barrett T. The Gene Expression Omnibus Database. Methods Mol Biol. 2016;5:3578–9.
14. Alshabi AM, et al. Identification of Crucial Candidate Genes and Pathways in Glioblastoma Multiform by Bioinformatics Analysis. Biomolecules. 2019;9:5.
15. Zhou L, et al. Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma. Mol Med Rep. 2018;18(5):4185–96.
16. Dennis G Jr, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4(5):3.
17. von Mering C, et al. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31(1):258–61.
18. Liu X, et al. IFI30 expression is an independent unfavourable prognostic factor in glioma. J Cell Mol Med. 2020;24(21):12433–43.
19. Zhu C, et al. IFI30 is a novel immune-related target with predicting value of prognosis and treatment response in glioblastoma. Onco Targets Ther. 2020;13:1129–43.
20. Davis ME. Glioblastoma: Overview of Disease and Treatment. Clin J Oncol Nurs. 2016;20(Suppl)2–8.
21. Cao M, et al. A four-gene signature-derived risk score for glioblastoma: prospects for prognostic and response predictive analyses. Cancer Biol Med. 2019;16(3):595–605.
22. Yin W, et al. Expression profile analysis identifies a novel five-gene signature to improve prognosis prediction of glioblastoma. Front Genet. 2019;10:419.

23. Chen S, et al. Lentivirus mediated γ-interferon-inducible lysosomal thiol reductase (GILT) knockdown suppresses human glioma U373MG cell proliferation. Biochem Biophys Res Commun. 2019;509(1):182–7.

24. Oldford SA, et al. Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients. Int Immunol. 2006;18(1):1591–602.

25. Xie L, et al. Autophagy-related gene P4HB: a novel diagnosis and prognosis marker for kidney renal clear cell carcinoma. Aging. 2020;12(2):1828–42.

26. Ma X, et al. P4HB modulates epithelial-mesenchymal transition and the β-catenin/Snail pathway influencing chemoresistance in liver cancer cells. Oncol Lett. 2020;20(1):257–65.

27. Ueda S, et al. Salivary NUS1 and RCN1 Levels as Biomarkers for Oral Squamous Cell Carcinoma Diagnosis. In Vivo. 2020;34(5):2353–61.

28. Liu X, et al. Downregulation of reticulocalbin-1 differentially facilitates apoptosis and necroptosis in human prostate cancer cells. Cancer Sci. 2018;109(4):1147–57.

29. Chen X, et al. Overexpression of RCN1 correlates with poor prognosis and progression in non-small cell lung cancer. Hum Pathol. 2019;83:140–8.

30. Alvaro-Benito M, et al. Human leukocyte Antigen-DM polymorphisms in autoimmune diseases. Open Biol. 2016;6(8):160165.

31. Vogt AB, et al. Quality control of MHC class II associated peptides by HLA-DM/H2-M. Semin Immunol. 1999;11(6):391–403.

32. Kobayashi S, et al. LGRS-positive colon cancer stem cells interconvert with drug-resistant LGRS-negative cells and are capable of tumor reconstitution. Stem Cells. 2012;30(12):2631–44.

33. Hang X, et al. Prognostic significance of microsatellite instability-associated pathways and genes in gastric cancer. Int J Mol Med. 2018;42(1):149–60.

34. Wang L, et al. Screening of differentially expressed genes associated with human glioblastoma and functional analysis using a DNA microarray. Mol Med Rep. 2015;12(2):1991–6.

35. Wu Y, et al. P4HB: A novel diagnostic and prognostic biomarker for bladder carcinoma. Oncol Lett. 2021;21(2):6.

36. Lu Y, et al. Significant Prognostic Value of the Autophagy-Related Gene P4HB in Bladder Urothelial Carcinoma. Front Oncol. 2020;10:1613.

37. Sun S, et al. Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways. Neuro Oncol. 2013;15(5):562–77.

38. Bettigole SE, Glimcher LH. Endoplasmic reticulum stress in immunity. Annu Rev Immunol. 2013;31:107–38.

39. Kurpińska A, et al. Proteomic characterization of early lung response to breast cancer metastasis in mice. Exp Mol Pathol. 2019;107:129–40.

40. Cooper CR, et al. Novel surface expression of reticulocalbin 1 on bone endothelial cells and human prostate cancer cells is regulated by TNF-alpha. J Cell Biochem. 2008;104(6):2298–309.

41. Huang ZH, et al. Reticulocalbin-1 knockdown increases the sensitivity of cells to Adriamycin in nasopharyngeal carcinoma and promotes endoplasmic reticulum stress-induced cell apoptosis. Cell Cycle. 2020;19(13):1576–89.

42. Jiang W, et al. IFI30 as a prognostic biomarker and correlation with immune infiltrates in glioma. Ann Transl Med. 2021;9(22):21–5569.

43. Chen Z, Hambardzumyan D. Immune Microenvironment in Glioblastoma Subtypes. Front Immunol. 2018;9:1004.

44. Zhou Y, et al. P4HB knockdown induces human HT29 colon cancer cell apoptosis through the generation of reactive oxygen species and inactivation of STAT3 signaling. Mol Med Rep. 2013;19(1):231–7.

45. Huang W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1–13.

46. Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.

47. Doncheva NT, et al. Cytoscape StringApp: Network Analysis and Visualization of Proteomics Data. J Proteome Res. 2019;18(2):323–32.

48. Tang Z, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–102.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.